journal
Journals Expert Review of Clinical Phar...

Expert Review of Clinical Pharmacology

https://read.qxmd.com/read/38652518/is-a-low-dose-of-dexamethasone-sufficient-to-prevent-paclitaxel-related-hypersensitivity-reactions-a-retrospective-study-in-patients-with-gynecologic-malignancy
#1
JOURNAL ARTICLE
Di Xiao, Zhiyun Yang, Yin Shi, Wenqing Yang, Yu Zhang
BACKGROUND: Paclitaxel hypersensitivity reactions (HSRs) are prevalent, especially in females. The common paclitaxel pretreatment, dexamethasone, may inhibit chemotherapy efficacy and accelerate tumor progression. We aimed to balance paclitaxel HSRs and the lowest dexamethasone dose for gynecologic malignancies. METHODS: We retrospectively examined 1,074 cycles of 3-weekly paclitaxel-containing treatment for 231 gynecologic malignancies at Xiangya Hospital. HSR incidence with different dexamethasone regimens was the primary outcome...
April 23, 2024: Expert Review of Clinical Pharmacology
https://read.qxmd.com/read/38632893/improvement-of-assessment-in-surrogate-endpoint-and-safety-outcome-of-single-arm-trials-for-anticancer-drugs
#2
REVIEW
Yafang Huang, Jinqiu Yuan
INTRODUCTION: Single-arm trials (SATs) and surrogate endpoints were adopted as pivotal evidence for accelerated approval of anticancer drugs for more than 30 years. However, concerns regarding clinical evidence quality in trials, particularly in the SATs of anticancer drugs have increasingly been raised. SAT may not always provide strong evidence due to the lack of control and endpoint of overall survival that is typically present in randomized controlled trials. AREAS COVERED: Clinical trial endpoint adjudication is a crucial factor in surrogate outcome measurement to ensure the data quality of the clinical trial of anticancer drugs...
April 17, 2024: Expert Review of Clinical Pharmacology
https://read.qxmd.com/read/38629382/treatment-adherence-and-adverse-event-management-in-chronic-lymphocytic-leukemia-challenges-and-strategies-for-the-future
#3
REVIEW
Maurlia D Upchurch, Benyam Muluneh
INTRODUCTION: There has been a paradigm shift in the treatment of chronic lymphocytic leukemia (CLL) over the past decade. With the advent of self-administered targeted oral anticancer agents (OAAs), the treatment of CLL has begun to shift from the infusion clinic to the patient's home. This introduced new challenges including patient non-adherence, class-specific adverse effects, and financial toxicity to treatment. In this paper, we discuss a structured approach to identifying and addressing barriers to optimal patient outcomes...
April 17, 2024: Expert Review of Clinical Pharmacology
https://read.qxmd.com/read/38629133/effectiveness-of-statins-in-people-living-with-hiv-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#4
REVIEW
Sai Santhosha Mrudula Alla, Dhruv J Shah, Vysakh Ratheesh, Deekshitha Alla, Thanmayee Tummala, Moksh S Khetan, Ritika J Shah, Ruth G Bayeh, Mahek Fatima, Sanah K Ahmed, Mert Sabıroğlu
INTRODUCTION: People living with HIV receiving (PLWH) statin therapy have shown improved lipid profiles. However, they are not free from side effects, thereby requiring strict monitoring of the therapy. The meta-analysis aims to analyze the effect of statins in PLWH, and critically appraise the effectiveness of statin therapy in PLWH. METHODS: The PubMed, Scopus, and Web of Science servers were used to conduct a systematic search in compliance with the PRISMA guidelines...
April 17, 2024: Expert Review of Clinical Pharmacology
https://read.qxmd.com/read/38626303/opioid-use-disorder-in-pediatric-populations-considerations-for-perioperative-pain-management-and-precision-opioid-analgesia
#5
REVIEW
Yun Han Chen, Anastasios Xenitidis, Paul Hoffman, Leslie Matthews, Swathi G Padmanabhan, Lakshmi Aravindan, Ruth Ressler, Inesh Sivam, Sahana Sivam, Chase F Gillispie, Senthilkumar Sadhasivam
INTRODUCTION: Opioids are commonly used for perioperative analgesia, yet children still suffer high rates of severe post-surgical pain and opioid-related adverse effects. Persistent and severe acute surgical pain greatly increases the child's chances of chronic surgical pain, long-term opioid use, and opioid use disorder. AREAS COVERED: Enhanced recovery after surgery (ERAS) protocols, are often inadequate in treating a child's severe surgical pain. Research suggests that 'older' and longer-acting opioids such as methadone are providing better methods to treat acute post-surgical pain...
April 16, 2024: Expert Review of Clinical Pharmacology
https://read.qxmd.com/read/38619027/exploring-the-impact-of-co-exposure-timing-on-drug-drug-interactions-in-signal-detection-through-spontaneous-reporting-system-databases-a-scoping-review
#6
REVIEW
Marianna Cocco, Carla Carnovale, Emilio Clementi, Maria Antonietta Barbieri, Vera Battini, Maurizio Sessa
INTRODUCTION: Drug-drug interactions (DDIs) are defined as the pharmacological effects produced by the concomitant administration of two or more drugs. To minimize false positive signals and ensure their validity when analyzing Spontaneous Reporting System (SRS) databases, it has been suggested to incorporate key pharmacological principles, such as temporal plausibility. AREAS COVERED: the scoping review of the literature was completed using MEDLINE from inception to March 2023...
April 15, 2024: Expert Review of Clinical Pharmacology
https://read.qxmd.com/read/38618915/engaging-patients-in-conversations-about-deprescribing
#7
EDITORIAL
Barbara Farrell
No abstract text is available yet for this article.
April 15, 2024: Expert Review of Clinical Pharmacology
https://read.qxmd.com/read/38603464/choosing-the-right-biologic-treatment-for-moderate-to-severe-plaque-psoriasis-the-impact-of-comorbidities
#8
REVIEW
Laura L Mateu-Arrom, Lluis L Puig
INTRODUCTION: Psoriasis is a chronic inflammatory skin disease often associated with several comorbidities, such as psoriatic arthritis, inflammatory bowel disease, obesity, diabetes mellitus or cardiovascular diseases, infections, or cancer, among others. With the progressive aging of the population, a growing number of patients with psoriasis can be expected to present multiple comorbidities. Currently, there is a wide range of biological treatments available for moderate to severe psoriasis, including tumor necrosis alpha (TNF) inhibitors, IL12/23 inhibitor, IL17 inhibitors, and IL23 inhibitors...
April 11, 2024: Expert Review of Clinical Pharmacology
https://read.qxmd.com/read/38571335/a-profile-of-azetukalner-for-the-treatment-of-epilepsy-from-pharmacology-to-potential-for-therapy
#9
REVIEW
Simona Lattanzi, Eugen Trinka, Stefano Meletti, Pasquale Striano, Sara Matricardi, Mauro Silvestrini, Francesco Brigo
INTRODUCTION: Epilepsies are a group of heterogeneous brain disorder, and antiseizure medications (ASMs) are the mainstay of treatment. Despite the availability of more than 30 drugs, at least one third of individuals with epilepsy are drug-resistant. This emphasizes the need for novel compounds that combine efficacy with improved tolerability. AREAS COVERED: A literature review on the pharmacology, efficacy, tolerability, and safety of azetukalner (XEN1101), a second-generation opener of neuronal potassium channels currently in Phase 3 development as ASM...
April 3, 2024: Expert Review of Clinical Pharmacology
https://read.qxmd.com/read/38511397/the-thiazide-like-diuretic-chlorthalidone-as-an-alternative-evidence-based-therapy-for-resistant-hypertension-in-patients-with-stage-4-chronic-kidney-disease
#10
EDITORIAL
Panagiotis I Georgianos, Vasilios Vaios, Ioannis Kontogiorgos, Maria Divani, Vassilios Liakopoulos
No abstract text is available yet for this article.
March 22, 2024: Expert Review of Clinical Pharmacology
https://read.qxmd.com/read/38471973/anti-obesity-medications-current-and-futurean-overview-of-therapeutic-options-of-obesity-management-in-india-the-integrated-diabetes-and-endocrinology-academy-idea-2023-congress-update
#11
REVIEW
Subir Ray, Nitin Kapoor, Neeta Deshpande, Sanjay Chatterjee, Janardanan Kumar, Om Tantia, Ghanshyam Goyal, Jagat Jyoti Mukherjee, Awadhesh Kumar Singh
INTRODUCTION: With newer anti-obesity medications (AOMs) being introduced at a rapid pace, it is prudent to make a concise and updated clinical practice document that may help busy clinicians in daily clinical practice. A group of metabolic physicians, diabetologists, endocrinologists, and bariatric surgeons assembled during the Integrated Diabetes and Endocrine Academy 2023 Congress (IDEACON, July 2023, Kolkata, India) to compile an update of pharmacotherapeutic options for managing people with obesity in India...
March 12, 2024: Expert Review of Clinical Pharmacology
https://read.qxmd.com/read/38441048/exposure-efficacy-relationship-of-vedolizumab-subcutaneous-and-intravenous-formulations-in-crohn-s-disease-and-ulcerative-colitis
#12
JOURNAL ARTICLE
Geert D'Haens, Maria Rosario, Daniel Polhamus, Nathanael L Dirks, Chunlin Chen, Krisztina Kisfalvi, Christian Agboton, Séverine Vermeire, Brian G Feagan, William J Sandborn
BACKGROUND AND AIMS: This posthoc analysis of the GEMINI and VISIBLE studies in ulcerative colitis (UC) and Crohn's Disease (CD) assessed exposure-efficacy of vedolizumab intravenous (IV) and subcutaneous (SC). METHODS: A previously described population pharmacokinetic model was used to predict average serum and trough concentrations at steady state (Cav,ss , Ctrough,ss ) and simulate the transition from vedolizumab IV to SC. Efficacy was defined as clinical remission at week 52: complete Mayo score ≤ 2 points and no individual subscore > 1 point (UC), and CD activity index score ≤ 150 points (CD)...
March 5, 2024: Expert Review of Clinical Pharmacology
https://read.qxmd.com/read/38413373/treatment-resistance-in-pancreatic-and-biliary-tract-cancer-molecular-and-clinical-pharmacology-perspectives
#13
REVIEW
Belén Toledo, Chiara Deiana, Fabio Scianò, Giovanni Brandi, Juan Antonio Marchal, Macarena Perán, Elisa Giovannetti
INTRODUCTION: Treatment resistance poses a significant obstacle in oncology, especially in biliary tract cancer (BTC) and pancreatic cancer (PC). Current therapeutic options include chemotherapy, targeted therapy, and immunotherapy. Resistance to these treatments may arise due to diverse molecular mechanisms, such as genetic and epigenetic modifications, altered drug metabolism and efflux, and changes in the tumor microenvironment. Identifying and overcoming these mechanisms is a major focus of research: strategies being explored include combination therapies, modulation of the tumor microenvironment, and personalized approaches...
February 27, 2024: Expert Review of Clinical Pharmacology
https://read.qxmd.com/read/38390721/antiretroviral-therapy-response-exploring-the-potential-influence-of-sars-cov-2
#14
EDITORIAL
Ahmad Z Al Meslamani
No abstract text is available yet for this article.
February 23, 2024: Expert Review of Clinical Pharmacology
https://read.qxmd.com/read/38379525/therapeutic-drug-monitoring-of-antifungal-therapies-do-we-really-need-it-and-what-are-the-best-practices
#15
JOURNAL ARTICLE
Johannes Boyer, Martin Hoenigl, Lisa Kriegl
INTRODUCTION: Despite advancements, invasive fungal infections (IFI) still carry high mortality rates, often exceeding 30%. The challenges in diagnosis, coupled with limited effective antifungal options, make managing IFIs complex. Antifungal drugs are essential for IFI management, but their efficacy can be diminished by drug-drug interactions and pharmacokinetic variability. Therapeutic Drug Monitoring (TDM), especially in the context of triazole use, has emerged as a valuable strategy to optimize antifungal therapy...
February 21, 2024: Expert Review of Clinical Pharmacology
https://read.qxmd.com/read/38349326/the-effect-of-epilepsy-and-antiseizure-medications-on-cardiac-autonomic-functions-in-children-with-epilepsy
#16
JOURNAL ARTICLE
Sherifa Ahmed Hamed, Ali Farag El Hadad, Mohammed Aboalwafa Aldawy
BACKGROUND: Autonomic manifestations have been frequently studied in adults with epilepsy. Here, we evaluated cardiac autonomic (ANS) functions in children with epilepsy in the interictal period and determined the risks for their dysfunctions. RESEARCH DESIGN AND METHODS: This study included 60 patients (boys = 25; girls = 35 age: 14.53 ± 2.54 yrs) and 25 controls. Patients were well-controlled on antiseizure medications (ASMs)...
February 13, 2024: Expert Review of Clinical Pharmacology
https://read.qxmd.com/read/38349034/centering-the-patient-in-decisions-about-opioid-tapering
#17
EDITORIAL
J J Fenton
No abstract text is available yet for this article.
February 13, 2024: Expert Review of Clinical Pharmacology
https://read.qxmd.com/read/38340012/integrating-clinical-pharmacology-and-artificial-intelligence-potential-benefits-challenges-and-role-of-clinical-pharmacologists
#18
REVIEW
Harmanjit Singh, Dwividendra Kumar Nim, Aaronbir Singh Randhawa, Saher Ahluwalia
INTRODUCTION: The integration of artificial intelligence (AI) into clinical pharmacology could be a potential approach for accelerating drug discovery and development, improving patient care, and streamlining medical research processes. AREAS COVERED: We reviewed the current state of AI applications in clinical pharmacology, focusing on drug discovery and development, precision medicine, pharmacovigilance, and other ventures. Key AI applications in clinical pharmacology are examined, including machine learning, natural language processing, deep learning, and reinforcement learning etc...
February 10, 2024: Expert Review of Clinical Pharmacology
https://read.qxmd.com/read/38339997/clinical-considerations-and-pharmacokinetic-interactions-between-hiv-and-tuberculosis-therapeutics
#19
REVIEW
Nicole F Maranchick, Awewura Kwara, Charles A Peloquin
INTRODUCTION: Tuberculosis(TB) is a leading infectious diseases cause of mortality worldwide,especially for people living with human immunodeficiency virus(PLWH). Treating TB in PLWH can be challenging due to numerous druginteractions. AREASCOVERED: Thisreview discusses drug interactions between antitubercular andantiretroviral drugs. Due to its clinical importance, initiation ofantiretroviral therapy in patients requiring TB treatment isdiscussed. Special focus is placed on the rifamycin class, as itaccounts for the majority of interactions...
February 10, 2024: Expert Review of Clinical Pharmacology
https://read.qxmd.com/read/38314564/the-future-of-pharmacology-education-the-veterinary-educators-in-pharmacology-special-interest-group-vepsig
#20
JOURNAL ARTICLE
Martin Hawes, Arno Werners
No abstract text is available yet for this article.
February 5, 2024: Expert Review of Clinical Pharmacology
journal
journal
41405
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.